- $194.29m
- -$2.45m
- $21.05m
Brief: Alector Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing
Brief: Alector Posts Q4 revenue USD 14.4 million
Alector Inc expected to post a loss of 46 cents a share - Earnings Preview
Alector Inc reports results for the quarter ended in September - Earnings Summary
Brief: Alector Reports Third Quarter 2022 Financial Results And Provides Business Update
Alector Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Alector Announces Promotion Of Clare Hunt To Chief People Officer
Alector up as trial begins for Alzheimer's drug
Brief: Alector Initiates Phase 1 Clinical Trial Of AL044 For The Treatment Of Alzheimer’S Disease (AD)
Alector slumps as Morgan Stanley sees no immediate catalyst for growth
Brief: Alector Reports Second Quarter 2022 Financial Results And Provides Business Update
Alector Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Alector sAYS Abbvie Has Decided To Terminate The Cd33 Collaboration Program
U.S. RESEARCH ROUNDUP-Bank Ozk, Bunge, Littelfuse
Brief: Alector Reports First Quarter 2022 Financial Results And Provides Business Update
Alector Inc expected to post earnings of 47 cents a share - Earnings Preview
Brief: Alector Presents Al001 (Latozinemab) Data From Ftd-C9orf72 Cohort Of INFRONT-2 Phase 2 Clinical Trial
Alector Inc reports results for the quarter ended in December - Earnings Summary
Brief: Alector Reports Q4 And Full Year 2021 Results